2022 - Research.com Best Female Scientist Award
The scientist’s investigation covers issues in Dementia, Internal medicine, Alzheimer's disease, Disease and Psychiatry. The Dementia study combines topics in areas such as Central nervous system disease, Parkinson's disease, Physical therapy, Neurology and Pediatrics. Her study in Parkinson's disease is interdisciplinary in nature, drawing from both Clinical psychology and Rating scale.
Within one scientific family, Karen Marder focuses on topics pertaining to Gastroenterology under Internal medicine, and may sometimes address concerns connected to Genetic epidemiology and Mutation. Her Alzheimer's disease study combines topics in areas such as Cognition and Audiology. Her work in Disease tackles topics such as Epidemiology which are related to areas like Cumulative incidence and Gerontology.
Karen Marder mainly investigates Disease, Internal medicine, Dementia, Parkinson's disease and Psychiatry. Her research integrates issues of Genetics, Prospective cohort study, Neurology and Pediatrics in her study of Disease. Her Pediatrics research incorporates elements of Neurological disorder, Epidemiology, Incidence and Cohort.
Her research on Internal medicine frequently connects to adjacent areas such as Pathology. Her work in Dementia covers topics such as Central nervous system disease which are related to areas like Severity of illness. As part of the same scientific family, she usually focuses on Huntington's disease, concentrating on Physical therapy and intersecting with Rating scale.
Karen Marder mostly deals with Disease, Internal medicine, LRRK2, Parkinson's disease and Dementia. Her work deals with themes such as Observational study, Psychiatry, Neurology, Confidence interval and Pediatrics, which intersect with Disease. Her work on Neuropsychology as part of her general Psychiatry study is frequently connected to Nothing, thereby bridging the divide between different branches of science.
Her LRRK2 study also includes fields such as
Her primary areas of investigation include Disease, Internal medicine, Parkinson's disease, LRRK2 and Genetics. Karen Marder has researched Disease in several fields, including Mutation and Neurology. Her work on Montreal Cognitive Assessment, Odds ratio, Severity of illness and Adverse effect as part of general Internal medicine study is frequently connected to Placebo-controlled study, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
She combines subjects such as Physical medicine and rehabilitation and Cohort with her study of Parkinson's disease. Her research investigates the connection between Genetics and topics such as Confidence interval that intersect with issues in Disease modification. Dementia is often connected to Gerontology in her work.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Updated research nosology for HIV-associated neurocognitive disorders
A. Antinori;G. Arendt;J. T. Becker;B. J. Brew.
Neurology (2007)
Unified huntington’s disease rating scale: Reliability and consistency
Karl Kieburtz;John B. Penney;Peter Corno;Neal Ranen.
Neurology (2001)
Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
Ming-Xin Tang;Diane Jacobs;Yaakov Stern;Karen Marder.
The Lancet (1996)
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Ellen Sidransky;Michael A. Nalls;Jan O. Aasly;Judith Aharon-Peretz.
The New England Journal of Medicine (2009)
Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease
Mike A Nalls;Nathan Pankratz;Christina M. Lill;Chuong B. Do.
Nature Genetics (2014)
Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset
Nancy S. Wexler;Judith Lorimer;Julie Porter;Fidela Gomez.
Proceedings of the National Academy of Sciences of the United States of America (2004)
The Apoe-Epsilon4 Allele and the Risk of Alzheimer Disease among African Americans, Whites, and Hispanics
Mingxin Tang;Yaakov Stern;Karen Marder;Karen L. Bell.
JAMA (1998)
Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease
Mike A. Nalls;Nathan Pankratz;Christina M. Lill;Chuong B. Do.
PMC (2014)
Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up.
D.P. Devanand;Kristin S. Michaels-Marston;Xinhua Liu;Gregory H. Pelton.
American Journal of Psychiatry (2000)
Incidence and predictors of seizures in patients with Alzheimer's disease.
Joan C. Amatniek;W. Allen Hauser;Carrie DelCastillo-Castaneda;Diane M. Jacobs.
Epilepsia (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Columbia University
Columbia University
The University of Texas Southwestern Medical Center
Tel Aviv University
Columbia University
Icahn School of Medicine at Mount Sinai
Columbia University
Mount Sinai Beth Israel
Columbia University
University of California, San Diego
Queen's University
University of California, Berkeley
RIKEN
Agricultural Research Service
University of Bologna
Leiden University
University of Michigan–Ann Arbor
University of Glasgow
International Institute for Applied Systems Analysis
Stony Brook University
University of Washington
University of Chicago
University of Oxford
Emory University
University of Zurich
Maastricht University